Ikena Oncology (IKNA) Competitors $1.15 +0.02 (+1.77%) Closing price 04:00 PM EasternExtended Trading$1.16 +0.02 (+1.30%) As of 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IKNA vs. PHAT, PROK, TVGN, BTMD, GNFT, KOD, AMRN, MNPR, SLDB, and SOPHShould you be buying Ikena Oncology stock or one of its competitors? The main competitors of Ikena Oncology include Phathom Pharmaceuticals (PHAT), ProKidney (PROK), Tevogen Bio (TVGN), biote (BTMD), Genfit (GNFT), Kodiak Sciences (KOD), Amarin (AMRN), Monopar Therapeutics (MNPR), Solid Biosciences (SLDB), and SOPHiA GENETICS (SOPH). These companies are all part of the "pharmaceutical products" industry. Ikena Oncology vs. Phathom Pharmaceuticals ProKidney Tevogen Bio biote Genfit Kodiak Sciences Amarin Monopar Therapeutics Solid Biosciences SOPHiA GENETICS Phathom Pharmaceuticals (NASDAQ:PHAT) and Ikena Oncology (NASDAQ:IKNA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk, earnings and community ranking. Does the MarketBeat Community favor PHAT or IKNA? Phathom Pharmaceuticals received 70 more outperform votes than Ikena Oncology when rated by MarketBeat users. Likewise, 72.46% of users gave Phathom Pharmaceuticals an outperform vote while only 58.82% of users gave Ikena Oncology an outperform vote. CompanyUnderperformOutperformPhathom PharmaceuticalsOutperform Votes10072.46% Underperform Votes3827.54% Ikena OncologyOutperform Votes3058.82% Underperform Votes2141.18% Which has stronger earnings and valuation, PHAT or IKNA? Ikena Oncology has lower revenue, but higher earnings than Phathom Pharmaceuticals. Ikena Oncology is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPhathom Pharmaceuticals$81.86M3.33-$201.59M-$5.24-0.74Ikena Oncology$659K84.21-$68.17M-$0.86-1.34 Which has more risk and volatility, PHAT or IKNA? Phathom Pharmaceuticals has a beta of 0.15, suggesting that its share price is 85% less volatile than the S&P 500. Comparatively, Ikena Oncology has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500. Do analysts rate PHAT or IKNA? Phathom Pharmaceuticals presently has a consensus target price of $17.60, indicating a potential upside of 351.28%. Ikena Oncology has a consensus target price of $3.00, indicating a potential upside of 160.87%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Phathom Pharmaceuticals is more favorable than Ikena Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phathom Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00Ikena Oncology 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do insiders & institutionals have more ownership in PHAT or IKNA? 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. Comparatively, 75.0% of Ikena Oncology shares are held by institutional investors. 23.0% of Phathom Pharmaceuticals shares are held by insiders. Comparatively, 5.9% of Ikena Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is PHAT or IKNA more profitable? Ikena Oncology has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -1,292.14%. Phathom Pharmaceuticals' return on equity of 0.00% beat Ikena Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Phathom Pharmaceuticals-1,292.14% N/A -79.57% Ikena Oncology N/A -36.88%-33.08% Does the media prefer PHAT or IKNA? In the previous week, Phathom Pharmaceuticals had 2 more articles in the media than Ikena Oncology. MarketBeat recorded 2 mentions for Phathom Pharmaceuticals and 0 mentions for Ikena Oncology. Phathom Pharmaceuticals' average media sentiment score of 1.08 beat Ikena Oncology's score of 1.06 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Phathom Pharmaceuticals Positive Ikena Oncology Positive SummaryPhathom Pharmaceuticals beats Ikena Oncology on 13 of the 19 factors compared between the two stocks. Get Ikena Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for IKNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IKNA vs. The Competition Export to ExcelMetricIkena OncologyBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$55.50M$2.93B$5.35B$8.38BDividend YieldN/A1.72%5.22%4.10%P/E Ratio-0.9330.5026.8419.71Price / Sales84.21400.15391.39116.98Price / CashN/A168.6838.2534.62Price / Book0.333.286.794.50Net Income-$68.17M-$72.17M$3.23B$248.18M7 Day Performance6.48%4.28%4.07%1.14%1 Month Performance0.88%7.62%12.52%15.20%1 Year Performance-16.67%-28.15%16.83%6.56% Ikena Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IKNAIkena Oncology3.0187 of 5 stars$1.15+1.8%$3.00+160.9%-19.3%$55.50M$659,000.00-0.9370Positive NewsGap UpPHATPhathom Pharmaceuticals3.8864 of 5 stars$3.15+0.3%$17.60+458.7%-59.8%$219.91M$81.86M-0.55110Positive NewsGap DownHigh Trading VolumePROKProKidney1.844 of 5 stars$0.75+4.0%$5.00+566.7%-79.6%$219.52M$76,000.00-1.363TVGNTevogen Bio2.8837 of 5 stars$1.19+9.2%$7.10+496.6%+48.7%$218.83MN/A0.003BTMDbiote2.8264 of 5 stars$3.99-0.3%$8.00+100.5%-29.4%$218.29M$197.19M15.35194GNFTGenfit0.9712 of 5 stars$4.36+1.4%$13.00+198.2%+8.0%$217.98M$67.00M0.00120Gap UpKODKodiak Sciences3.6832 of 5 stars$4.13+9.5%$9.00+117.9%+24.5%$217.87MN/A-1.1390Earnings ReportAnalyst RevisionGap DownAMRNAmarin0.3455 of 5 stars$10.42+0.1%$7.00-32.8%-36.9%$215.79M$228.61M-115.78360MNPRMonopar Therapeutics2.9031 of 5 stars$35.10-11.0%$55.33+57.6%+1,090.5%$214.64MN/A-17.8210Gap DownSLDBSolid Biosciences4.2895 of 5 stars$2.90+5.1%$15.67+440.2%-67.7%$213.91M$8.09M-0.95100Earnings ReportAnalyst ForecastAnalyst RevisionSOPHSOPHiA GENETICS1.7949 of 5 stars$3.18+8.5%$6.80+113.8%-36.7%$212.07M$67.17M-2.92520Gap Up Related Companies and Tools Related Companies PHAT Competitors PROK Competitors TVGN Competitors BTMD Competitors GNFT Competitors KOD Competitors AMRN Competitors MNPR Competitors SLDB Competitors SOPH Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IKNA) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ikena Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ikena Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
